In the future, determining the precise mechanism of ccf DNA release in PD patients would add further value to ccf mtDNA’s potential to serve as a reliable, non-invasive approach to monitoring responses to medical treatment during therapy. This evidence concerns the gene PITX1 and Parkinson disease.